Mach 1 Financial Group LLC Invests $878,000 in Merck & Co., Inc. $MRK

Posted by on May 21st, 2026

Mach 1 Financial Group LLC acquired a new position in shares of Merck & Co., Inc. (NYSE:MRK – Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 8,343 shares of the company’s stock, valued at approximately $878,000.

A number of other large investors have also modified their holdings of MRK. D.A. Davidson & CO. grew its stake in shares of Merck & Co., Inc. by 4.4% during the fourth quarter. D.A. Davidson & CO. now owns 576,959 shares of the company’s stock worth $60,731,000 after purchasing an additional 24,576 shares in the last quarter. Farther Finance Advisors LLC grew its stake in shares of Merck & Co., Inc. by 48.9% during the fourth quarter. Farther Finance Advisors LLC now owns 97,818 shares of the company’s stock worth $10,296,000 after purchasing an additional 32,114 shares in the last quarter. Coldstream Capital Management Inc. grew its stake in shares of Merck & Co., Inc. by 12.7% during the third quarter. Coldstream Capital Management Inc. now owns 123,366 shares of the company’s stock worth $10,364,000 after purchasing an additional 13,940 shares in the last quarter. NEOS Investment Management LLC grew its stake in shares of Merck & Co., Inc. by 39.9% during the third quarter. NEOS Investment Management LLC now owns 347,684 shares of the company’s stock worth $29,181,000 after purchasing an additional 99,074 shares in the last quarter. Finally, Campbell Capital Management Inc. acquired a new position in shares of Merck & Co., Inc. during the third quarter worth $1,866,000. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Stock Performance

NYSE MRK opened at $113.01 on Thursday. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06. Merck & Co., Inc. has a 1 year low of $75.40 and a 1 year high of $125.14. The company has a market capitalization of $279.12 billion, a PE ratio of 31.83, a P/E/G ratio of 2.57 and a beta of 0.18. The company has a fifty day moving average of $115.82 and a two-hundred day moving average of $109.92.

Merck & Co., Inc. (NYSE:MRK – Get Free Report) last released its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.47) by $0.19. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The company had revenue of $16.29 billion during the quarter, compared to the consensus estimate of $15.85 billion. During the same quarter in the prior year, the firm posted $2.22 earnings per share. Merck & Co., Inc.’s revenue for the quarter was up 4.9% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. As a group, analysts expect that Merck & Co., Inc. will post 5.16 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts recently commented on the stock. Barclays assumed coverage on shares of Merck & Co., Inc. in a research note on Friday, February 20th. They set an “overweight” rating and a $140.00 target price for the company. Cantor Fitzgerald boosted their target price on shares of Merck & Co., Inc. from $116.00 to $120.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 4th. UBS Group boosted their target price on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a “buy” rating in a research note on Monday, April 13th. Weiss Ratings downgraded shares of Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a research note on Friday, May 15th. Finally, Citigroup assumed coverage on shares of Merck & Co., Inc. in a research note on Wednesday, May 6th. They set a “neutral” rating and a $125.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and seven have assigned a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $128.18.

Check Out Our Latest Analysis on Merck & Co., Inc.

About Merck & Co., Inc.

(Free Report)

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

Featured Stories

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.